Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Eagle Pharmaceuticals Inc's Business Segments
Eagle Pharmaceuticals Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
-
Largest Segment
-
Total Revenue
$ 65
Regions Reported
-
Eagle Pharmaceuticals Inc does not report a distinct business-segment axis in its filings - its disaggregated revenue is disclosed by product and service category instead. See the Product & Service breakdown below.
Revenue by Product & Service Category - FY
- Product66.5%
- Royalty33.5%
Revenue by Product & Service Category - FY
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Product | $ 43 | 66.5% |
| Royalty | $ 22 | 33.5% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Description of Eagle Pharmaceuticals Inc
Eagle Pharmaceuticals Inc. is a specialty pharmaceutical company that is headquartered in Woodcliff Lake, New Jersey, United States. The company was founded in 2007, and it operates as a subsidiary of Eagle Parent Holdings LLC. It is involved in the development and commercialization of injectable drugs that address unmet medical needs.
Eagle Pharmaceuticals focuses on drugs that are difficult to administer or have a limited shelf life. The company's products are designed to improve the safety, efficacy, and convenience of existing therapies. The company has a dedicated research and development team that works on developing the most innovative drugs.
The company's portfolio of products includes injectable drugs for critical care, oncology, and orphan diseases. Among its most notable products are Ryanodex, a treatment for malignant hyperthermia, and Bendeka/Benqim, a treatment for chronic lymphocytic leukemia. Additionally, it offers injectable drugs for the treatment of pain, infections, and rheumatoid arthritis.
Eagle Pharmaceuticals' business model is based on licensing, developing, and partnering with other pharmaceutical companies to market and distribute its products. The company's primary target is the United States market, but it has operations in Europe, the Middle East, and Asia as well. Its products are marketed through a network of distributors and partners.
The company has partnerships with several pharmaceutical companies, including Teva, Lupin, and Dr. Reddy's Laboratories. Eagle Pharmaceuticals has also established partnerships with academic medical centers and research organizations to advance its drug development program.
In conclusion, Eagle Pharmaceuticals Inc. is a specialty pharmaceutical company that focuses on the development and commercialization of injectable drugs for difficult-to-treat medical conditions. Its innovative products are aimed at improving the safety, effectiveness, and convenience of existing therapies. The company is committed to building strong partnerships with other companies and research organizations to advance its drug development program.
Eagle Pharmaceuticals focuses on drugs that are difficult to administer or have a limited shelf life. The company's products are designed to improve the safety, efficacy, and convenience of existing therapies. The company has a dedicated research and development team that works on developing the most innovative drugs.
The company's portfolio of products includes injectable drugs for critical care, oncology, and orphan diseases. Among its most notable products are Ryanodex, a treatment for malignant hyperthermia, and Bendeka/Benqim, a treatment for chronic lymphocytic leukemia. Additionally, it offers injectable drugs for the treatment of pain, infections, and rheumatoid arthritis.
Eagle Pharmaceuticals' business model is based on licensing, developing, and partnering with other pharmaceutical companies to market and distribute its products. The company's primary target is the United States market, but it has operations in Europe, the Middle East, and Asia as well. Its products are marketed through a network of distributors and partners.
The company has partnerships with several pharmaceutical companies, including Teva, Lupin, and Dr. Reddy's Laboratories. Eagle Pharmaceuticals has also established partnerships with academic medical centers and research organizations to advance its drug development program.
In conclusion, Eagle Pharmaceuticals Inc. is a specialty pharmaceutical company that focuses on the development and commercialization of injectable drugs for difficult-to-treat medical conditions. Its innovative products are aimed at improving the safety, effectiveness, and convenience of existing therapies. The company is committed to building strong partnerships with other companies and research organizations to advance its drug development program.
Eagle Pharmaceuticals Inc. is a specialized pharmaceutical company dedicated to the development and commercialization of unique injectable products that aim to meet significant medical needs, particularly in areas that currently lack adequate treatments. The company operates primarily in three therapeutic segments: oncology, critical care, and orphan products.
Segments
Eagle Pharmaceuticals Inc. operates mainly in one comprehensive segment, which encompasses the development and commercialization of pharmaceutical products with a strong emphasis on injectables. This segment involves intense research and development efforts, partnerships, and collaborations aimed at delivering robust solutions to healthcare providers and patients facing serious medical conditions.
Products and Services
1. Oncology Products
Eagle Pharmaceuticals has a distinguished lineup of products targeting various types of cancers:
- Bendeka (Bendamustine Hydrochloride Injection): This is a liquid, concentrated formulation of bendamustine, a chemotherapeutic agent aimed at treating chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma. The concentrated nature of Bendeka allows for a shorter infusion time compared to traditional formulations, enhancing patient convenience and compliance.
- Pemfexy (Pemetrexed for Injection): Pemfexy serves as a branded alternative to pemetrexed, an established treatment for malignant pleural mesothelioma and metastatic non-squamous non-small cell lung cancer (NSCLC). By providing a high-quality, effective injectable form of this key therapeutic, Pemfexy continues to offer hope for patients battling these challenging conditions.
- Ryanodex (Dantrolene Sodium for Injection): While primarily utilized within the oncology framework, Ryanodex has broader implications as a crucial treatment for malignant hyperthermia (MH), a life-threatening reaction that can occur during anesthesia. The formulation allows for rapid infusion, facilitating immediate action in emergency situations associated with MH episodes.
Critical Care Products
In addition to its oncology offerings, Eagle Pharmaceuticals boasts several critical care products designed to manage acute medical conditions:
- Argatroban: This anticoagulant medication is utilized to prevent and treat thrombosis in patients with heparin-induced thrombocytopenia (HIT), a severe complication of heparin therapy. Argatroban is essential in critical care settings, especially during surgical procedures or when treating patients who cannot be administered heparin.
- Ryanodex: Already noted in the oncology section, Ryanodex also plays a pivotal role in critical care by acting as a rapid treatment option for malignant hyperthermia, illustrating its dual significance in both oncology and critical care metrics.
Orphan Products
Eagle Pharmaceuticals recognizes the challenges posed by rare diseases and has committed to developing orphan products tailored to meet these needs:
- Bendeka again becomes pertinent in this category due to its use in treating cancers, which, despite being classified as treatments for more common malignancies, are nonetheless pivotal in the realm of orphan designations due to the small patient populations encountering chronic lymphocytic leukemia and associated blood cancers.
Licensing and Collaborations
Eagle Pharmaceuticals actively pursues partnerships and licensing agreements to amplify its market reach and expedite the development of products. For instance:
- Collaboration with Teva Pharmaceuticals: This partnership focuses on the development and distribution of bendamustine hydrochloride injection in selected global markets, allowing for shared resources and expertise that enhance market access and patient availability.
Conclusion
Eagle Pharmaceuticals Inc. stands out in the pharmaceutical landscape with its dedication to innovative injectable products across key therapeutic areas: oncology, critical care, and orphan diseases. Through a combination of unique formulations, strategic collaborations, and a firm commitment to addressing unmet medical needs, the company positions itself as an essential player in enhancing patient outcomes and providing effective treatment options.
Segments
Eagle Pharmaceuticals Inc. operates mainly in one comprehensive segment, which encompasses the development and commercialization of pharmaceutical products with a strong emphasis on injectables. This segment involves intense research and development efforts, partnerships, and collaborations aimed at delivering robust solutions to healthcare providers and patients facing serious medical conditions.
Products and Services
1. Oncology Products
Eagle Pharmaceuticals has a distinguished lineup of products targeting various types of cancers:
- Bendeka (Bendamustine Hydrochloride Injection): This is a liquid, concentrated formulation of bendamustine, a chemotherapeutic agent aimed at treating chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma. The concentrated nature of Bendeka allows for a shorter infusion time compared to traditional formulations, enhancing patient convenience and compliance.
- Pemfexy (Pemetrexed for Injection): Pemfexy serves as a branded alternative to pemetrexed, an established treatment for malignant pleural mesothelioma and metastatic non-squamous non-small cell lung cancer (NSCLC). By providing a high-quality, effective injectable form of this key therapeutic, Pemfexy continues to offer hope for patients battling these challenging conditions.
- Ryanodex (Dantrolene Sodium for Injection): While primarily utilized within the oncology framework, Ryanodex has broader implications as a crucial treatment for malignant hyperthermia (MH), a life-threatening reaction that can occur during anesthesia. The formulation allows for rapid infusion, facilitating immediate action in emergency situations associated with MH episodes.
Critical Care Products
In addition to its oncology offerings, Eagle Pharmaceuticals boasts several critical care products designed to manage acute medical conditions:
- Argatroban: This anticoagulant medication is utilized to prevent and treat thrombosis in patients with heparin-induced thrombocytopenia (HIT), a severe complication of heparin therapy. Argatroban is essential in critical care settings, especially during surgical procedures or when treating patients who cannot be administered heparin.
- Ryanodex: Already noted in the oncology section, Ryanodex also plays a pivotal role in critical care by acting as a rapid treatment option for malignant hyperthermia, illustrating its dual significance in both oncology and critical care metrics.
Orphan Products
Eagle Pharmaceuticals recognizes the challenges posed by rare diseases and has committed to developing orphan products tailored to meet these needs:
- Bendeka again becomes pertinent in this category due to its use in treating cancers, which, despite being classified as treatments for more common malignancies, are nonetheless pivotal in the realm of orphan designations due to the small patient populations encountering chronic lymphocytic leukemia and associated blood cancers.
Licensing and Collaborations
Eagle Pharmaceuticals actively pursues partnerships and licensing agreements to amplify its market reach and expedite the development of products. For instance:
- Collaboration with Teva Pharmaceuticals: This partnership focuses on the development and distribution of bendamustine hydrochloride injection in selected global markets, allowing for shared resources and expertise that enhance market access and patient availability.
Conclusion
Eagle Pharmaceuticals Inc. stands out in the pharmaceutical landscape with its dedication to innovative injectable products across key therapeutic areas: oncology, critical care, and orphan diseases. Through a combination of unique formulations, strategic collaborations, and a firm commitment to addressing unmet medical needs, the company positions itself as an essential player in enhancing patient outcomes and providing effective treatment options.